Filtern
Dokumenttyp
- Vortrag (3)
Sprache
- Englisch (3)
Referierte Publikation
- nein (3)
Schlagworte
- Reference materials (3) (entfernen)
Organisationseinheit der BAM
Eingeladener Vortrag
- nein (3)
The aim of task 1.4 within the EMPIR project 18HLT01 MetVesII is to produce low-RI solid particles with an effective RI between 1.37 and 1.42. To prepare these low-RI solid particles, polymer cores will be coated with a silica shell. Although the bulk RI of polymers, such as polystyrene (RI = 1.59) and PMMA (RI = 1.49), and fused silica (RI = 1.46) are higher than desired, an effective RI below 1.42 will be achieved by using a mesoporous silica shell with tuneable shell-thickness and a polymer core with sufficiently small size. This approach has four advantages: (1) monodisperse commercial polymer particles and silica shell chemistry are available, (2) low-RI solid particles will have a tuneable size and RI, (3) fluorescence can be added by incorporating fluorescent dyes into the polymer cores via an established staining procedure, and (4) fluorescent dyes within the polymer cores are shielded against influences from the sample matrix, e.g. fluorescence quenching effects altering the emission properties of the reference materials.
BAM provides leading expertise in preparation, characterisation and application of fluorescent reference standards and biomedical relevant nanomaterials, as well as in traceable, absolute, and quantitative fluorometric measurements of transparent and scattering systems in the ultraviolet, visible, and near infrared spectral region. BAM will prepare solid low-RI particles in WP1, will develop reference methods to determine the fluorescence intensity and RI of reference materials in WP2, and will measure the fluorescence intensity of EVs in biological test samples of WP3.
Standardisation of concentration measurements of extracellular vesicles for medical diagnoses
(2020)
Extracellular vesicles (EVs) are cell-derived particles in body fluids, which have excellent potential as next generation biomarkers for the early diagnosis of common diseases, such as cancer and thrombosis. This project aims to tap into the clinical potential of EVs by developing traceable measurements of number concentration, size distribution, refractive index (RI) and fluorescence intensity of cell-specific EVs in human blood and urine.
To realise our aims, we will develop synthetic reference materials with physical properties resembling EVs (WP1), instrumentation and procedures to standardise EV measurements in clinical laboratories (WP2), and ready-to-use biological test samples (WP3). These will then be evaluated in an inter-laboratory comparison study across a range (>20) of standard flow cytometers in clinical labs (WP4).